The microsite is supported by AbbVie.

As a global, research-driven biopharmaceutical company, AbbVie is committed to treating serious, mostly chronic diseases. Research and innovation are the foundation of the company’s operations. Therapeutic areas include dermatology.

Highlights
Video contributions
Professional article
View Post
  • This content is machine translated SGDV Congress 2024: Atopic dermatitis and psoriasis

Happy patient, happy doctor?

At the AbbVie Symposium as part of the SGDV Congress 2024, Prof. Dr. Curdin Conrad (CHUV Lausanne) and Prof. Dr. Kilian Eyerich (University of Freiburg, Germany) discussed the concept of “Happy Patient, Happy Doctor?”, among other things. The focus was on atopic dermatitis (AD) and psoriasis (PsO), two chronic inflammatory skin diseases that are both physically and psychologically stressful [1, 2].
View Post
View Post
  • This content is machine translated Sponsored Content: Inflammatory skin diseases

“New horizons” in the treatment of inflammatory skin diseases

The field of inflammatory skin diseases is constantly evolving. Updates on current standard treatments, innovative therapy options and artificial intelligence were presented at two accredited live webinars entitled “New Horizons in Dermatology” in June 2024. Below you will find a summary of the most important concepts presented.
View Post
View Post
  • This content is machine translated Interview with Prof. Thomas Kündig (USZ) and Prof. Diego Kyburz (USB)

“You have to stop treating psoriasis as just a skin disease”.

In Switzerland, psoriasis affects about 1 to 3 percent of the population [1]. About one in three psoriasis patients also suffers from psoriatic arthritis (PsA), a chronic inflammatory systemic disease that can manifest itself in arthritis, enthesitis, and dactylitis, among other things [2, 3]. If left untreated, PsA can result in joint destruction and even disability [2]. In the following interview, dermatologist Prof. Thomas Kündig and rheumatologist Prof. Diego Kyburz discuss the interdisciplinary management of this complex disease and elaborate on two current therapeutic options [4, 5].
View Post
View Post
  • This content is machine translated Sponsored Content: Cumulative Life Course Impairment (CLCI)

The burden of psoriasis gets under your skin

Psoriasis is a complex chronic disease that can go beyond skin lesions and affect various aspects of life. The underlying inflammation, which can lead to a variety of concomitant diseases, plays a decisive role [1-3]. Early systemic treatment may show promise for achieving complete skin improvement as well as reducing inflammation and potential comorbidities [4-5].
View Post
View Post
  • This content is machine translated Sponsored Content: Atopic dermatitis: Roadshow 2024

Better standard of care through joint decision-making

The first Swiss Atopic Dermatitis (AD) Roadshow took place at the beginning of February 2024. AD expert Prof. Jonathan Silverberg from the George Washington University School of Medicine and Health Sciences in Washington, DC, USA, spoke at five Swiss centers about the various systemic AD treatments. The focus was on individualized patient-centered therapy to raise the standard of care for AD. In the post-Roadshow interview, Prof. Silverberg shares his experiences and thoughts on shared decision-making and the Minimal Disease Activity (MDA) concept.
View Post
View Post
  • This content is machine translated SGDV Congress 2023: Psoriasis and atopic dermatitis

On the trail with Sherlock Holmes and CSI – Mystery cases solved

At the “somewhat different” AbbVie Symposium at this year’s Swiss Dermatology Congress (SGDV Congress) in Lausanne, experts did some excellent detective work: a missing person was found and the mysteriously altered behavior of a patient was also clarified. Find out here how Sherlock Holmes and the CSI agent were able to solve the cases at the symposium.
View Post
View Post
  • This content is machine translated Atopic dermatitis

Achieving high treatment goals with the Minimal Disease Activity concept

Patients with moderate to severe atopic dermatitis suffer from the physical and psychological effects of the disease and yet do not receive adequate treatment with systemic therapies, or often only after a delay [1-3]. The Minimal Disease Activity approach aims to consistently identify patients who are candidates for advanced treatment, combining the treat-to-target concept with shared decision-making between patients and physicians [4].
View Post
View Post
  • This content is machine translated CME Atopic Dermatitis

State-of-the-Art of Targeted Immunotherapy for Adult Atopic Dermatitis.

Basile Darbellay, MD, MD-PhD (Cabinet Dr. Basile Darbellay Orsières) & Prof. Christoph Schlapbach, MD, PhD (Inselspital Bern) Atopic dermatitis is characterized by eczematous skin lesions, severe pruritus, and great heterogeneity in clinical features and severity [1]. Targeted systemic immunotherapies are now available for patients with moderate to severe AD [2]. In this CME, the most important pivotal studies on these modern therapeutic approaches will be presented.
CME-Test
View Post